Fulcrum Therapeutics

United States
Primghar, Iowa, United States, 02139

Company profile

Fulcrum Therapeutics company profile

Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases. The company develops a proprietary product engine that is employed to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairment and disability. It is focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. Founded in 2016, the company is based in Cambridge, Massachusetts, United States.

Business identity

Contact email
[email protected]
Phone number
(617)651-8851
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$50,000+
Founded
2016-01-01, Year

Headquarters

Postal code
02139
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
9
Total equity funding
$778.3M
Last funding
Post IPO Equity / $175M / 2025-12-10
Last equity funding
Post IPO Equity / $175M
Investors
16
Lead investors
3
Founders
6
Articles
208
Exited on
2019-07-17

Founders and investors

Founders

Bradley BernsteinDanny ReinbergJeannie T. LeeMichael GreenRobert J. GouldRudolf Jaenisch

Lead investors

Foresite CapitalGoogle VenturesThird Rock Ventures

Investors

FidelityForesite CapitalS32Samsara BioCapitalSanofi